查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1356769

女性不孕诊断与治疗市场报告：2030 年趋势、预测与竞争分析

Female Infertility Diagnosis and Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

女性不孕诊断和治疗的趋势和预测

预计到2030年，全球女性不孕诊断和治疗市场将达20亿美元，2024年至2030年年复合成长率为7.7%。这个市场的主要促进因素是唐氏症、ONTD 和其他疾病等遗传疾病的患病、对可避免治疗的认识不断增强以及辅助生殖技术的进步。全球女性不孕诊疗市场前景广阔，医院/诊所、居家医疗、病理/诊断中心市场蕴藏商机。

女性不孕诊疗市场洞察

Lucintel 预测，由于治疗女性不孕的技术不断进步，包括体外受精 (IVF)、人工授精 (AI-IUI) 和冷冻胚胎移植 (FET) 等，辅助生殖技术将在预测期内继续增长。预计增幅最高的是

在这个市场中，由于拥有庞大的基本客群以及医生越来越多地采用新技术先进的做法，医院和诊所可能仍然是最大的细分市场。

由于不孕相关问题的普遍存在和医疗保健支出的增加，预计亚太地区在预测期内将出现最高的增长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要要素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些，由于材料或产品替代导致市场占有率下降的威胁有多大？
  • Q.1.1.过去年度发生了哪些类型的併购，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球女性不孕诊断与治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业促进因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球女性不孕诊断及治疗市场趋势（2018-2023）及预测（2024-2030）
  • 全球女性不孕诊断与治疗市场（依治疗方式）
    • 药品
    • 外科手术
    • 子宫腔内人工授精
    • 辅助生殖技术
  • 全球女性不孕诊断和治疗市场（按诊断）
    • 排卵测试
    • 造影
    • 子宫镜检查
    • 影像检查
    • 卵巢储备测试
    • 荷尔蒙水平测试
    • 基因检测
    • 其他的
  • 全球女性不孕诊断和治疗市场（按最终用途）
    • 医院/诊所
    • 居家医疗
    • 病理/诊断中心
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球女性不孕诊断与治疗市场（按地区）
  • 北美女性不孕诊疗市场
  • 欧洲女性不孕诊疗市场
  • 亚太女性不孕诊疗市场
  • 其他地区女性不孕诊疗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球女性不孕诊断和治疗市场成长机会（按治疗）
    • 全球女性不孕诊断和治疗市场成长机会（按诊断）
    • 按最终用途的全球女性不孕诊断和治疗市场的成长机会
    • 全球女性不孕诊断与治疗市场按地区成长机会
  • 全球女性不孕诊疗市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球女性不孕诊断和治疗市场的容量
    • 全球女性不孕诊断和治疗市场的合併和收购
    • 认证和许可

第7章主要企业概况

  • Bayer AG
  • Church & Dwight
  • Genea
  • Pfizer
  • Vitrolife Sweden AB
  • Esco Group
  • Fairhaven Health
  • Ferring BV
简介目录

Female Infertility Diagnosis and Treatment Trends and Forecast

The future of the global female infertility diagnosis and treatment market looks promising with opportunities in the hospitals & clinic, homecare, and pathology & diagnostic centers markets. The global female infertility diagnosis and treatment market is expected to reach an estimated $2.0 billion by 2030 with a CAGR of 7.7% from 2024 to 2030. The major drivers for this market are growing prevalence of genetic disorders, such as Down syndrome, ONTD, and other disorders, increasing awareness towards avialable treatment, and technological advancement of assisted reproductive technology.

A more than 150-page report is developed to help in your business decisions.

Female Infertility Diagnosis and Treatment by Segment

The study includes a forecast for the global female infertility diagnosis and treatment by treatment, diagnosis, end use, and region.

Female Infertility Diagnosis and Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Drugs
  • Surgery
  • Intrauterine Insemination
  • Assisted Reproductive Technology

Female Infertility Diagnosis and Treatment Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Ovulation Testing
  • Hysterosalpingography
  • Hysteroscopy
  • Imaging Testing
  • Ovarian Reserve Testing
  • Hormonal Level Testing
  • Genetic Testing
  • Others

Female Infertility Diagnosis and Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals and Clinics
  • Homecare
  • Pathology and Diagnostic Centers
  • Others

Female Infertility Diagnosis and Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Female Infertility Diagnosis and Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies female infertility diagnosis and treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the female infertility diagnosis and treatment companies profiled in this report include-

  • Bayer Ag
  • Church & Dwight
  • Genea
  • Pfizer
  • Vitrolife Sweden Ab
  • Esco Group
  • Fairhaven Health
  • Ferring B.V.

Female Infertility Diagnosis and Treatment Market Insights

Lucintel forecasts that assisted reproductive technology is expected to witness highest growth over the forecast period due to on-going technological advancements, which includes in vitro fertilization (IVF), artificial insemination(AI-IUI), and frozen embryo transfer(FET for treating infertility in women.

Within this market, hospitals and clinics will remain the largest segment due to presence of large customer base and growing adoption of new technologically advanced practices by doctors.

Asia Pacific is expected to witness highest growth over the forecast period due to prevalence of infertility-related issues and increasing expenditure on healthcare in the region.

Features of the Global Female Infertility Diagnosis and Treatment Market

Market Size Estimates: Female infertility diagnosis and treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Female infertility diagnosis and treatment market size by treatment, diagnosis, end use, and region. in terms of value ($B).

Regional Analysis: Female infertility diagnosis and treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatments, diagnosis, end uses, and region.s for the female infertility diagnosis and treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the female infertility diagnosis and treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the female infertility diagnosis and treatment market size?

Answer: The global female infertility diagnosis and treatment market is expected to reach an estimated $2.0 billion by 2030.

Q.2. What is the growth forecast for female infertility diagnosis and treatment market?

Answer: The global female infertility diagnosis and treatment market is expected to grow with a CAGR of 7.7% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the female infertility diagnosis and treatment market?

Answer: The major drivers for this market are growing prevalence of genetic disorders, such as Down syndrome, ONTD, and other disorders, increasing awareness towards avialable treatment, and technological advancement of assisted reproductive technology.

Q.4. What are the major segments for female infertility diagnosis and treatment market?

Answer: The future of the female infertility diagnosis and treatment market looks promising with opportunities in the hospitals & clinic, homecare, and pathology & diagnostic centers markets.

Q.5. Who are the key female infertility diagnosis and treatment market companies?

Answer: Some of the key female infertility diagnosis and treatment companies are as follows:

  • Bayer AG
  • Church & Dwight
  • Genea
  • Pfizer
  • Vitrolife Sweden AB
  • Esco Group
  • Fairhaven Health
  • Ferring B.V.

Q.6. Which female infertility diagnosis and treatment market segment will be the largest in future?

Answer: Lucintel forecasts that assisted reproductive technology is expected to witness highest growth over the forecast period due to on-going technological advancements, which includes in vitro fertilization (IVF), artificial insemination(AI-IUI), and frozen embryo transfer(FET for treating infertility in women.

Q.7. In female infertility diagnosis and treatment market, which region is expected to be the largest in next 5 years?

Answer: Asia Pacific is expected to witness highest growth over the forecast period due to prevalence of infertility-related issues and increasing expenditure on healthcare in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the female infertility diagnosis and treatment market by treatment (drugs, surgery, intrauterine insemination, and assisted reproductive technology), diagnosis (ovulation testing, hysterosalpingography, hysteroscopy, imaging testing, ovarian reserve testing, hormonal level testing, genetic testing, and others), end use (hospitals & clinics, homecare, pathology & diagnostic centers, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.1. 1. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Female Infertility Diagnosis and Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Female Infertility Diagnosis and Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Female Infertility Diagnosis and Treatment Market by Treatment
    • 3.3.1: Drugs
    • 3.3.2: Surgery
    • 3.3.3: Intrauterine Insemination
    • 3.3.4: Assisted Reproductive Technology
  • 3.4: Global Female Infertility Diagnosis and Treatment Market by Diagnosis
    • 3.4.1: Ovulation Testing
    • 3.4.2: Hysterosalpingography
    • 3.4.3: Hysteroscopy
    • 3.4.4: Imaging Testing
    • 3.4.5: Ovarian Reserve Testing
    • 3.4.6: Hormonal Level Testing
    • 3.4.7: Genetic Testing
    • 3.4.8: Others
  • 3.5: Global Female Infertility Diagnosis and Treatment Market by End Use
    • 3.5.1: Hospitals and Clinics
    • 3.5.2: Homecare
    • 3.5.3: Pathology and Diagnostic Centers
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Female Infertility Diagnosis and Treatment Market by Region
  • 4.2: North American Female Infertility Diagnosis and Treatment Market
    • 4.2.2: North American Female Infertility Diagnosis and Treatment Market by End Use: Hospitals and Clinics, Homecare, Pathology and Diagnostic Centers, and Others
  • 4.3: European Female Infertility Diagnosis and Treatment Market
    • 4.3.1: European Female Infertility Diagnosis and Treatment Market by Treatment: Drugs, Surgery, Intrauterine Insemination, and Assisted Reproductive Technology
    • 4.3.2: European Female Infertility Diagnosis and Treatment Market by End Use: Hospitals and Clinics, Homecare, Pathology and Diagnostic Centers, and Others
  • 4.4: APAC Female Infertility Diagnosis and Treatment Market
    • 4.4.1: APAC Female Infertility Diagnosis and Treatment Market by Treatment: Drugs, Surgery, Intrauterine Insemination, and Assisted Reproductive Technology
    • 4.4.2: APAC Female Infertility Diagnosis and Treatment Market by End Use: Hospitals and Clinics, Homecare, Pathology and Diagnostic Centers, and Others
  • 4.5: ROW Female Infertility Diagnosis and Treatment Market
    • 4.5.1: ROW Female Infertility Diagnosis and Treatment Market by Treatment: Drugs, Surgery, Intrauterine Insemination, and Assisted Reproductive Technology
    • 4.5.2: ROW Female Infertility Diagnosis and Treatment Market by End Use: Hospitals and Clinics, Homecare, Pathology and Diagnostic Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Female Infertility Diagnosis and Treatment Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Female Infertility Diagnosis and Treatment Market by Diagnosis
    • 6.1.3: Growth Opportunities for the Global Female Infertility Diagnosis and Treatment Market by End Use
    • 6.1.4: Growth Opportunities for the Global Female Infertility Diagnosis and Treatment Market by Region
  • 6.2: Emerging Trends in the Global Female Infertility Diagnosis and Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Female Infertility Diagnosis and Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Female Infertility Diagnosis and Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bayer AG
  • 7.2: Church & Dwight
  • 7.3: Genea
  • 7.4: Pfizer
  • 7.5: Vitrolife Sweden AB
  • 7.6: Esco Group
  • 7.7: Fairhaven Health
  • 7.8: Ferring B.V.